Shopping Cart
Remove All
Your shopping cart is currently empty
Xentuzumab
🥰Excellent
Catalog No. T76795Cas No. 1417158-65-6
Alias BI 836845
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours.
Xentuzumab
🥰Excellent
Purity: 95.21%
Catalog No. T76795Alias BI 836845Cas No. 1417158-65-6
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $347 | In Stock | In Stock | |
| 5 mg | $886 | In Stock | In Stock | |
| 10 mg | $1,450 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:95.21%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
| Description | Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours. |
| In vitro | After 5 or 10 days of incubation, single-agent Xentuzumab(XENT)or ENZA reduced the viability of VCaP, DuCaP, and MDA PCa 2b cells in a dose-dependent manner. Combination therapy further decreased cell viability compared to monotherapy; likewise, treatment with XENT+ENZA resulted in a significant reduction in the expression of cell cycle genes, ubiquitin-conjugating enzyme E2 C (UBE2C), cyclin-dependent kinase 1 (CDK1), and cell division cycle protein 20 (CDC20) compared to single-agent treatment.[1]. |
| In vivo | Monotherapy with ENZA did not inhibit tumor growth. However, the addition of Xentuzumab(XENT)rendered the tumors sensitive to ENZA again, leading to a significant reduction in tumor volume[1]. |
| Synonyms | BI 836845 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | ＜ 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Molecular Weight | 143.7 kDa |
| Cas No. | 1417158-65-6 |
| Color | Transparent |
| Appearance | Liquid |
Storage & Solubility Information
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Xentuzumab | purchase Xentuzumab | Xentuzumab cost | order Xentuzumab | Xentuzumab chemical structure | Xentuzumab in vivo | Xentuzumab in vitro | Xentuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.